| 摘要 |
The present invention in the field of immunotherapy, provides a method for predicting the likelihood of tumor shrinkage in response to administration of immunotherapeutic agents to patients having tumors or cancer, especially lymphoma or myeloma. The present invention further provides methods for optimizing a beneficial outcome of immunotherapy for treating cancer, immune system diseases and infections diseases in an anergic patient by boosting the immune responsiveness of the patient before beginning the immunotherapy, and methods for determining the optimum amount and schedule of an immunotherapeutic agent to administer to treat cancer and immune diseases. |
